Ann: Race continues Board renewal - appoints new Chair, page-98

In your expert opinion how would zantrene be priced for AML as the first approved indication? as this would likely set the bench mark and place a ceiling on all other indications into the future.

My assumption is Damian has come on board and given RAC some home truths on their strategy and where to put priority focus. Not to say anything in regards to clinical strategy is changing, but maybe commercially the story they choose to push is not AML, they all ready have an agreement with Astex, bring in some partners on other indications before they drop results.

I expect we see an update on AML strategy in the quarterly

Other than that it’s all guns blazing on breast/cardio/FTO & they won’t want anything of low hanging fruit to chop the value